Peptide ligation using enzyme
PBP-type TE enzymes facilitate efficient peptide ligation and modification by forming amide bonds, addressing the limitations of existing techniques with improved stability and selectivity, allowing for N-terminus modifications and non-peptidic structure introduction.
Patent Information
- Application Number
- JP2021157054
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-09-27
- Publication Date
- 2024-11-20
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing peptide modification techniques face challenges in achieving high selectivity and stability under mild conditions, with limited enzyme tools available for introducing modifications, particularly at the N-terminus of peptides.
Utilization of PBP-type thioesterase (PBP-type TE) enzymes, which can catalyze both intramolecular and intermolecular amidation reactions, specifically forming amide bonds between the C-terminus of a donor substrate and the N-terminus of an acceptor substrate, including activation of the C-terminal hydrophobic D-amino acid carboxyl group.
The method provides enhanced resistance to degrading enzymes and eliminates the need for protecting group manipulation, enabling selective N-terminus modification and introduction of non-peptidic structures, with improved peptide ligation efficiency.
Smart Images

Figure 2024161633000001 
Figure 2024161633000002
Abstract
Description
[Technical field]
[0001] The present invention relates to the enzymatic production of peptides and the modification of peptides. [Background technology]
[0002] Peptides (including oligopeptides, polypeptides, and proteins in this specification) are fundamental biomolecules that support life activities, and techniques for visualization or functional control by artificial modification greatly contribute to elucidating life phenomena. In addition, peptides themselves, as typified by antibodies and insulin, are important modalities for drug discovery. For this reason, site-specific modification methods for peptides have been vigorously studied (Non-Patent Document 1), and attempts have been made to create new peptides. In general, peptides have low resistance to high temperature conditions and organic solvents, and have many exposed reaction sites with similar chemical characteristics, so the challenge is how to introduce modifications mildly and highly selectively. Enzyme catalysts that have mild reaction conditions and high molecular recognition ability are expected to be used as protein modification tools, and enzymes such as sortase, butelase I, and subtilisin mutant enzymes have been proposed as N-terminal modification tools for peptides (Non-Patent Document 2). However, each of these has advantages and disadvantages (high substrate specificity and stability of the substrate itself), and the targets that can be targeted are limited, so it is desirable to expand the repertoire of enzyme tools.
[0003] Meanwhile, the inventors have previously discovered a novel enzyme family, penicillin-binding protein thioesterase (PBP-type TE), from soil bacteria (actinomycetes), and found that this enzyme efficiently catalyzes the intramolecular amidation (cyclization) reaction of peptides (Patent Document 1). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Patent Application Publication WO2019 / 216248 [Non-patent literature]
[0005] [Non-Patent Document 1] Hoyt, EA et al., Nat. Rev. Chem. 3, 147-171 (2019). [Non-Patent Document 2] Rosen, CB & Francis, MB Nat. Chem. Biol. 13, 697-705 (2017). Summary of the Invention [Problem to be solved by the invention]
[0006] New enzymatic tools for peptide synthesis and new techniques for modifying peptides are desirable. [Means for solving the problem]
[0007] In order to solve the above problems, the present inventors have conducted extensive research and found that PBP-type TE can catalyze not only intramolecular amidation but also intermolecular amidation. Specifically, they found that PBP-type TE can site-selectively bind a donor peptide substrate (referred to as a donor substrate) to the N-terminus of an acceptor peptide substrate (referred to as an acceptor substrate) via an amide bond. Based on these findings, the present inventors have completed the present invention.
[0008] That is, the present invention provides the following. (1) A method for producing a ligated peptide, which comprises forming an amide bond between the C-terminus of a donor substrate and the N-terminus of an acceptor substrate using a PBP-type TE as a catalyst. (2) The PBP-type TE is an enzyme having the amino acid sequence shown in SEQ ID NO: 2 or a mutant enzyme thereof, and the mutant enzyme has any of the following amino acid sequences: (a) an amino acid sequence having 38% or more identity to the amino acid sequence shown in SEQ ID NO: 2; (b) an amino acid sequence in which several or several tens of amino acids have been substituted, deleted, inserted or added in the amino acid sequence shown in SEQ ID NO: 2; or (c) an amino acid sequence encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1; and having peptide ligation activity equal to or greater than that of an enzyme having the amino acid sequence shown in SEQ ID NO: 2. (3) The method according to (1) or (2), wherein the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively, and the carboxyl group of the C-terminal hydrophobic D-amino acid is activated. (4) The method according to (3), wherein the activation of the carboxyl group of the C-terminal hydrophobic D-amino acid is carried out by providing a thioester-type leaving group. (5) A method for producing a modified peptide, comprising forming an amide bond between the C-terminus of a donor substrate containing a modifying group and the N-terminus of an acceptor substrate using a PBP-type TE as a catalyst. (6) The PBP-type TE is an enzyme having the amino acid sequence shown in SEQ ID NO: 2 or a mutant enzyme thereof, and the mutant enzyme has any of the following amino acid sequences: (a) an amino acid sequence having 38% or more identity to the amino acid sequence shown in SEQ ID NO: 2; (b) an amino acid sequence in which several or several tens of amino acids have been substituted, deleted, inserted or added in the amino acid sequence shown in SEQ ID NO: 2; or (c) an amino acid sequence encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1; and having peptide ligation activity equal to or greater than that of an enzyme having the amino acid sequence shown in SEQ ID NO: 2. (7) The method according to (5) or (6), wherein the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively, and the carboxyl group of the C-terminal hydrophobic D-amino acid is activated. (8) The method according to (7), wherein the activation of the carboxyl group of the C-terminal hydrophobic D-amino acid is carried out by providing a thioester-type leaving group. (9) A peptide ligation kit including PBP-type TE. (10) A kit for producing modified peptides, including PBP-type TE. (11) The kit according to (10), further comprising a donor substrate comprising a modifying group. Effect of the Invention
[0009] The present invention provides a new enzymatic tool for peptide synthesis and a new peptide modification technique. The ligated peptide obtained by the present invention has an amide bond containing a D-amino acid, and therefore has improved resistance to decomposition enzymes compared to peptides consisting of only L-amino acids. Since the peptide ligation of the present invention is enzymatic, there is no need for the complicated procedures of adding and deprotecting protecting groups as in chemical synthesis. Furthermore, the present invention provides a method for selectively modifying the N-terminus of a peptide or protein. This modification method can also be used to introduce a non-peptidic structure into the N-terminus of a peptide or protein. [Brief description of the drawings]
[0010] [Figure 1] The upper part of Figure 1 shows a scheme of peptide ligation reaction using PBP-type TE. The lower part of Figure 1 shows LC-MS charts analyzing the ligation reaction products using the donor and acceptor substrates shown in the upper part of Figure 1. +Nsm16 shows a chart of the products obtained from a reaction system containing the enzyme, and substrate only shows a chart of the products obtained from a reaction system not containing the enzyme. [Diagram 2]Figure 2 shows LC-MS charts of the ligation reaction products when a small modified peptide was used as a donor substrate. "All in" shows the chart of the products obtained from the reaction system containing the enzyme, and "substrate only" shows the chart of the products obtained from the reaction system not containing the enzyme. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] In a first aspect, the present invention provides a method for producing a ligated peptide, which is characterized by using a PBP-type TE as a catalyst to generate an amide bond between the C-terminus of a donor substrate and the N-terminus of an acceptor substrate.
[0012] PBP-type TEs are a novel enzyme family discovered by the inventors in soil bacteria (actinomycetes) and are a family of cyclases involved in non-ribosomal peptide biosynthesis (Kuranaga, T. et al., Angew. Chem. Int. Ed. 2018, 57, 9447-9451, and Matsuda, K. et al. Nat. Catl. 2020, 3, 507-515).
[0013] The present inventors have found for the first time that PBP-type TE can catalyze not only peptide cyclization but also peptide ligation. In this specification, peptide ligation refers to the formation of an amide bond (peptide bond) between the C-terminal amino acid residue of a donor substrate and the N-terminal amino acid residue of an acceptor substrate. The PBP-type TE that can be used in the present invention is capable of catalyzing peptide ligation. In this specification, the term "ligation" does not include peptide cyclization.
[0014] The PBP-type TE used in the peptide ligation of the present invention can be selected from known ones. An example thereof is the enzyme Nsm16 derived from Streptomyces noursei NBRC 15452, but is not limited thereto. PBP-type TEs including the enzyme Nsm16 can be obtained using known cloning methods.
[0015] In the present invention, the enzyme Nsm16 is preferably used. The base sequence of DNA encoding the enzyme Nsm16 is shown in SEQ ID NO: 1. The amino acid sequence of the enzyme Nsm16 is shown in SEQ ID NO: 2. That is, in the present invention, an enzyme having the amino acid sequence shown in SEQ ID NO: 2 or an enzyme having an amino acid sequence encoded by the base sequence shown in SEQ ID NO: 1 is preferably used.
[0016] Mutants of the enzyme Nsm16 that have peptide ligation activity equivalent to or greater than that of the enzyme Nsm16 are also preferably used in the present invention. Peptide ligation activity equivalent to or greater than that of the enzyme Nsm16 refers to about 50% or more of the activity of the enzyme Nsm16, preferably about 70% or more, more preferably about 80% or more, and even more preferably about 90% or more. The peptide ligation activity of an enzyme can be measured by reacting a donor substrate and an acceptor substrate and analyzing the product. For example, the peptide ligation activity may be measured by reacting a test enzyme with a donor substrate and an acceptor substrate according to the procedure described in the Examples of this specification, and subjecting the resulting reaction solution to LC-MS analysis to measure the amount of ligation product.
[0017] Specific examples of mutants of the enzyme Nsm16 include, but are not limited to, enzymes having an amino acid sequence with about 35% or more, for example about 38% or more, preferably about 50% or more, more preferably about 70% or more, and even more preferably about 90% or more identity to the amino acid sequence shown in SEQ ID NO: 2, and having peptide ligation activity equivalent to or greater than that of the enzyme Nsm16. The identity of amino acid sequences can be determined using known search tools such as BLASTP.
[0018] Further specific examples of mutants of the enzyme Nsm16 include, but are not limited to, enzymes having an amino acid sequence in which several or several tens of amino acids have been substituted, deleted, inserted or added in the amino acid sequence shown in SEQ ID NO:2, and having peptide ligation activity equivalent to or higher than that of the enzyme Nsm16. Here, several refers to 2, 3, 5, 4, 6, 7, 8 or 9. Several tens refers to about 10 to about 90, for example, about 20, about 30, about 40, about 50, about 60, about 70, about 80 or about 90, or a number between these values. The substitution of an amino acid in the amino acid sequence may be with any amino acid, but is preferably with an amino acid having similar properties and / or structure. For example, the amino acids in the following brackets may be substituted for each other: (G, A), (K, R, H), (D, E), (N, Q), (S, T, Y), (C, M), (F, W, Y, H), (V, L, I).
[0019] Further specific examples of mutants of the enzyme Nsm16 include, but are not limited to, enzymes having an amino acid sequence encoded by a base sequence that hybridizes to a base sequence complementary to the base sequence shown in SEQ ID NO:1 under stringent conditions, and having peptide ligation activity equivalent to or greater than that of the enzyme Nsm16.
[0020] Stringent conditions are known to those skilled in the art and include, for example, the following conditions: Hybridization for 16 to 24 hours in a buffer containing 0.25 M Na2HPO4, pH 7.2, 7% SDS, 1 mM EDTA, and 1 × Denhardt's solution at a temperature of 60 to 68 ° C, preferably 65 ° C, and more preferably 68 ° C, and further washing for 15 minutes twice in a buffer containing 20 mM Na2HPO4, pH 7.2, 1% SDS, and 1 mM EDTA at a temperature of 60 to 68 ° C, preferably 65 ° C, and more preferably 68 ° C; or Prehybridization was performed overnight at 42°C in a hybridization solution containing 25% formamide, or for more stringent conditions, 50% formamide, 4x SSC (sodium chloride / sodium citrate), 50 mM HEPES pH 7.0, 10x Denhardt's solution, and 20 μg / ml denatured salmon sperm DNA, followed by washing in a buffer containing 1x SSC and 0.1% SDS at 37°C, or for more stringent conditions, in a buffer containing 0.5x SSC and 0.1% SDS at 42°C, or for even more stringent conditions, in a buffer containing 0.2x SSC and 0.1% SDS at 65°C. Stringent conditions are not limited to the above examples.
[0021] The mutant of the enzyme Nsm16 may be naturally occurring or may be artificially produced by, for example, genetic engineering techniques. For example, the mutant of the enzyme Nsm16 may be a PBP-type TE possessed by an actinomycete other than Streptomyces noursei NBRC 15452.
[0022] The enzyme Nsm16 and its mutants may be produced by cloning the Nsm16 gene or its homologs or orthologs to obtain genes encoding these enzymes. For example, the enzyme Nsm16 may be obtained by the method described in the Examples of this specification.
[0023] As used herein, a peptide refers to a molecule in which amino acid residues are linked by peptide bonds. The number of amino acid residues is two or more. As used herein, oligopeptides, polypeptides, and proteins are also included in peptides. As used herein, it is not necessary that all bonds between amino acid residues in a peptide are peptide bonds. The amino acids constituting a peptide may be those contained in natural proteins, or those not contained in natural proteins (e.g., β-alanine, γ-aminobutyric acid, ornithine, homocysteine, etc.). The amino acids constituting a peptide may be L- or D-forms. The amino acids constituting a peptide may be those present in living organisms, or may be those artificially synthesized. A peptide may contain a non-peptide structure or a modifying group (which will be described later). As used herein, the left end of a peptide is the N-terminus, and the right end is the carboxyl terminus.
[0024] The acceptor substrate may be any peptide. The type of amino acid residues constituting the acceptor substrate is not particularly limited. The number of amino acid residues constituting the acceptor substrate is also not particularly limited, but the fewer the number the better.
[0025] The donor substrate may be a peptide containing any type and number of amino acid residues. Preferably, the second amino acid residue from the C-terminus of the donor substrate is a cationic amino acid. Preferably, the C-terminal amino acid residue of the donor substrate is a hydrophobic amino acid. Preferably, the C-terminal amino acid residue of the donor substrate is in the D-form. More preferably, the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively.
[0026] Cationic amino acids are known and include, but are not limited to, lysine, arginine, histidine, and ornithine. Cationic amino acids may also be referred to as amino acids that have an isoelectric point greater than 7.
[0027] Hydrophobic amino acids are also known and include, but are not limited to, leucine, isoleucine, valine, alanine, tryptophan, phenylalanine, and methionine. A hydrophobic amino acid may be an amino acid that has a higher hydrophobic index than glycine.
[0028] It is essential that the carboxyl group of the C-terminal amino acid of the donor substrate is activated. Examples of activation include, but are not limited to, esterification. Examples of esterification include, but are not limited to, thioesterification, alkyl esterification (e.g., methyl esterification, ethyl esterification, etc.). It is preferable to activate the carboxyl group of the C-terminal D-amino acid of the donor substrate by thioesterification, that is, by adding a thioester-type leaving group. It is preferable to perform thioesterification using N-acetylcysteamine (formation of SNAC body).
[0029] The donor substrate may contain a non-peptide structure. The non-peptide structure refers to a structure not contained in natural peptides, and the type and structure thereof are not particularly limited. Examples of the non-peptide structure include, but are not limited to, labels such as biotin, fluorescein, and rhodamine, luciferin, PEG, sugars, lipids, and nucleic acids. The non-peptide structure may be naturally derived or artificially created. The non-peptide structure may be a modifying group described below. A non-peptide structure can be imparted to an acceptor substrate using a donor substrate containing a PBP-type TE and a non-peptide structure. Similarly, an acceptor substrate can be modified using a donor peptide containing a modifying group, not limited to a non-peptide structure.
[0030] Therefore, in another aspect, the present invention provides a method for producing a modified peptide, which is characterized by using a PBP-type TE as a catalyst to form an amide bond between the C-terminus of a donor substrate containing a modifying group and the N-terminus of an acceptor substrate.
[0031] The above method can be used as a method for selectively modifying the N-terminus of a target peptide (acceptor substrate). The modifying group refers to a group that modifies a target peptide, and its type and structure are not particularly limited. The modifying group may have a peptidic structure or a non-peptidic structure. Examples of the modifying group include, but are not limited to, fluorescent labels, luminescent labels, radioactive labels, biotin, avidin, other peptides or proteins, such as histidine tags, maltose binding protein, and glutathione-S-transferase tags, luciferase, antibodies or portions thereof, antigens or portions thereof, sugars, lipids, and nucleic acids. The modifying group may be naturally derived or artificially created. The modifying group may have the non-peptidic structure described above.
[0032] In a further embodiment, the present invention provides a kit for peptide ligation comprising a PBP-type TE. Usually, the kit is accompanied by an instruction manual. The kit may comprise a donor substrate and / or an acceptor substrate. The kit may comprise, for example, a lyophilized PBP-type TE from the viewpoint of storage and stability.
[0033] In a further embodiment, the present invention provides a kit for producing a modified peptide, comprising a PBP-type TE. Usually, the kit is accompanied by an instruction manual. The kit may comprise a donor substrate comprising a modification group. The kit may comprise an acceptor substrate. The kit may comprise, for example, a lyophilized PBP-type TE for storage and stability.
[0034] In a further embodiment, the present invention provides a donor substrate for use in peptide ligation by PBP-type TE. Preferably, the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively. Preferably, the C-terminal amino acid of the donor substrate is activated. More preferably, the C-terminal amino acid of the donor substrate is in the SNAC form at its carboxyl group.
[0035] Unless otherwise specified, the terms used in this specification are to be interpreted as they are commonly understood in the fields of chemistry, biology, biochemistry, medicine, pharmacology, etc. In this specification, when "about" is placed before a numerical value, it represents the numerical value ±20%, preferably the numerical value ±10%, and more preferably the numerical value ±5%.
[0036] The present invention will be described in more detail and specifically below by showing examples. However, the examples are for illustrative purposes only and should not be construed as limiting the scope of the present invention. EXAMPLES
[0037] 1. Preparation of Recombinant Enzyme Nsm16 Polymerase KOD One (Toyobo) was used to amplify a DNA fragment encoding the enzyme Nsm16 from the genomic DNA of Streptomyces noursei NBRC 15452. The primer set used for amplification was as follows (uppercase letters). An EcoRI recognition site was added to the forward primer, and a HindIII recognition site was added to the reverse primer (underlined parts of SEQ ID NOs: 3 and 4). Nsm16_Fw: 5'-ccg gaattc GTGCACGGGGACTCAGCGGATCC-3' (SEQ ID NO:3) Nsm16_Rv: 5'-ccc aagctt TTAGTGCGGCCGTGCGCCGTGG-3' (SEQ ID NO:4) The amplified fragment was inserted into the EcoRI / HindIII site in the multiple cloning site of pET-28a(+) (Novagen) to obtain a recombinant enzyme Nsm16 expression vector (Nsm16-pET28a).
[0038] The expression vector obtained above was introduced into E. coli BL231(DE3), and a single colony was inoculated into 10 mL of 2xYT medium (1.6% Bacto peptone, 1.0% Bacto Yeast Extract, 0.5% NaCl) containing 50 μg / mL kanamycin and cultured overnight at 37 °C to obtain a seed culture. 2.0 mL of the culture was transferred to 200 mL of 2xYT medium containing 50 μg / mL kanamycin and cultured at 37 °C for 3 hours. The culture was cooled on ice, and 0.1 mL of IPTG was added to induce the expression of the recombinant enzyme Nsm16. E. coli was cultured overnight at 16 °C. The bacteria were collected by centrifugation (3500 x g, 10 min) and disrupted using an ultrasonic homogenizer. After removing the residue by centrifugation (17000xg, 10 min), the fraction containing the soluble protein was applied to a Ni-NTA affinity column (Merck Millipore) equilibrated with wash buffer (20mM Tris-HCl pH8.0, 150mM NaCl, 20mM imidazole). The column was washed with wash buffer and eluted with 500mM imidazole wash buffer. The column eluate was concentrated with an Amicon Ultra 0.5mL filter (Merck Millipore). The concentration of the protein solution was measured with a Bio-Rad protein assay kit. In this experiment, the recombinant enzyme Nsm16 was obtained as a protein with a histidine tag attached to the N-terminus. Its amino acid sequence is shown in SEQ ID NO:5.
[0039] The recombinant enzyme Nsm16 thus obtained was used in the following peptide ligation experiment.
[0040] 2. Synthesis of substrate The donor and acceptor substrates used in this experiment were synthesized by solid-phase peptide synthesis. The solid-phase peptide synthesis protocol is shown below. Solid Phase Peptide Synthesis Protocol Step 1: The Fmoc group of the solid-supported peptide was removed by using a 20% piperidine / DMF solution (10 min, room temperature). Step 2: The resin in the reaction vessel was washed with DMF (x3) and CH2Cl2 (x3). Step 3: To a solution of F-moc protected building block (4 eq) was added DIC (4 eq) in NMP and Oxyma (4 eq in DMF). After 2-3 min of preactivation, the mixture was injected into the reaction vessel. The resulting mixture was stirred for 30 min. Step 4: The resin in the reaction vessel was washed with DMF (x3) and CH2Cl2 (x3). The amino acids were concentrated onto the solid support by repeating steps 1-4. Thioesterification of the N-terminal amino acid of the donor substrate was carried out by standard methods using N-acetylcysteamine. The donor substrates used in this study were: Biotinylated Glycine-D-Tryptophan-D-Arginine-D-Phenylalanine SNAC Complex It was. The acceptor substrates used in this study were: D-Phenylalanine-Glycine-Glycine-D-Tryptophan-D-Arginine-D-Phenylalanine It was.
[0041] 3. Peptide Ligation (1) The donor and acceptor substrates shown in the upper part of Figure 1 were ligated with the enzyme Nsm16. The reaction was started by adding 1.0 μM of the enzyme Nsm16 to a reaction mixture containing 200 μM of the donor substrate and 800 μM of the acceptor substrate in 20 mM Tris-HCl (pH 8.0). After incubation at 30°C for 2 hours, the reaction was stopped by adding an equal volume of 0.1% TFA. The sample was diluted with an equal volume of methanol and then centrifuged at 20000xg for 10 minutes. The resulting supernatant was analyzed by LC-MS (amaZon SL-NPC) operating in positive mode. The LC-MS was coupled to a Shimadzu HPLC system. Separation was performed using a Cosmosil 5C18-MS-II 2.0x150mm column (Nacalai Tesque). Mobile phases A and B were water + 0.05% TFA and acetonitrile + 0.05% TFA, respectively. The gradient mode was from 10% to 90% mobile phase B over 20 min, and the flow rate was 0.2 ml min -1 The sample was eluted at .
[0042] The results of LC-MS analysis are shown in the lower part of Figure 1. In the enzyme-added system, the production of hydrolysates and ligated peptides (labeled "Peptide conjugate" in the figure, a peak with a retention time of approximately 9.7 minutes) was confirmed in association with the reduction of the donor substrate and acceptor substrate.
[0043] 4. Peptide Ligation (2) Next, in addition to the donor substrate used in the above peptide ligation (1), we investigated peptide ligation reactions using smaller donor substrates (see Figure 2). The small donor substrates used in this experiment were: Biotinylated D-tryptophan-D-arginine-D-phenylalanine SNAC complex Biotinylated D-arginine-D-phenylalanine SNAC complex Biotinylated D-phenylalanine SNAC complex It was. The acceptor substrate used in this experiment was the same as in peptide ligation (1) above. The reaction conditions were the same as in peptide ligation (1) above.
[0044] The LC-MS analysis results shown in Figure 2 showed that ligation products were observed regardless of the donor substrate used (indicated as Conjugate in the figure, peaks at retention times of approximately 9.5, 9.8, 8.9, and 10.2 minutes from the top), and the smaller the donor substrate, the higher the yield of the ligation product tended to be. The yield of the ligation product was highest when the donor substrate was biotinylated arginine-SNAC D-phenylalanine. When a donor substrate lacking a cationic amino acid residue (arginine) was used, a ligation product was obtained, but only in small amounts (peak at retention time of approximately 10.2 minutes). These results suggested that PBP-type TE recognizes the cationic amino acid-hydrophobic amino acid motif in the donor substrate. [Industrial Applicability]
[0045] The present invention provides a new enzyme tool for peptide synthesis and a new peptide modification technique, and is therefore applicable in the fields of chemistry, biology, biochemistry, medicine, pharmacology, etc. The present invention is applicable, for example, to the development and production of new drugs and new research reagents. [Sequence List Free Text]
[0046] SEQ ID NO:1 shows the base sequence of DNA encoding the enzyme Nsm16. SEQ ID NO:2 shows the amino acid sequence of the enzyme Nsm16. SEQ ID NO:3 shows the nucleotide sequence of the forward primer (including the EcoRI recognition site) for amplifying a DNA fragment encoding the enzyme Nsm16. SEQ ID NO: 4 shows the nucleotide sequence of the reverse primer (including the HindIII recognition site) for amplifying a DNA fragment encoding the enzyme Nsm16. Sequence number: 5 shows the amino acid sequence of the recombinant enzyme Nsm16 (including a histidine tag) obtained in the Examples.
Claims
1. A method for producing a ligated peptide, comprising forming an amide bond between the C-terminus of a donor peptide substrate (donor substrate) and the N-terminus of an acceptor peptide substrate (acceptor substrate) using penicillin-binding protein thioesterase (PBP-type TE) as a catalyst.
2. The PBP-type TE is an enzyme having the amino acid sequence shown in SEQ ID NO: 2 or a mutant enzyme thereof, and the mutant enzyme has any of the following amino acid sequences: (a) an amino acid sequence having 38% or more identity to the amino acid sequence shown in SEQ ID NO: 2; (b) an amino acid sequence in which several or several tens of amino acids have been substituted, deleted, inserted or added in the amino acid sequence shown in SEQ ID NO: 2, or (c) an amino acid sequence encoded by a base sequence that hybridizes under stringent conditions to a base sequence complementary to the base sequence shown in SEQ ID NO: 1; and having peptide ligation activity equal to or greater than that of an enzyme having the amino acid sequence shown in SEQ ID NO:
2.
3. The method according to claim 1 or 2, wherein the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively, and the carboxyl group of the C-terminal hydrophobic D-amino acid is activated.
4. The method according to claim 3, wherein the activation of the carboxyl group of the C-terminal hydrophobic D-amino acid is carried out by providing a thioester type leaving group.
5. A method for producing a modified peptide, comprising forming an amide bond between the C-terminus of a donor substrate containing a modifying group and the N-terminus of an acceptor substrate using PBP-type TE as a catalyst.
6. The PBP-type TE is an enzyme having the amino acid sequence shown in SEQ ID NO: 2 or a mutant enzyme thereof, and the mutant enzyme has any of the following amino acid sequences: (a) an amino acid sequence having 38% or more identity to the amino acid sequence shown in SEQ ID NO: 2; (b) an amino acid sequence in which several or several tens of amino acids have been substituted, deleted, inserted or added in the amino acid sequence shown in SEQ ID NO: 2, or (c) an amino acid sequence encoded by a base sequence that hybridizes under stringent conditions to a base sequence complementary to the base sequence shown in SEQ ID NO: 1; and having peptide ligation activity equal to or greater than that of an enzyme having the amino acid sequence shown in SEQ ID NO:
2.
7. The method according to claim 5 or 6, wherein the second residue from the C-terminus and the C-terminal residue of the donor substrate are a cationic amino acid and a hydrophobic D-amino acid, respectively, and the carboxyl group of the C-terminal hydrophobic D-amino acid is activated.
8. 8. The method according to claim 7, wherein the activation of the carboxyl group of the C-terminal hydrophobic D-amino acid is carried out by providing a thioester type leaving group.
9. A peptide ligation kit including PBP-type TE.
10. A kit for producing modified peptides, comprising PBP-type TE.
11. The kit of claim 10 , further comprising a donor substrate comprising a modifying group.
Citation Information
Patent Citations
Peptide macrocyclase
WO2019216248A1
